Abdul Mannan: Advancing VWF Activity Testing Beyond VWF:RCo in Clinical Laboratories
Abdul Mannan, Consultant Hematologist at Betsi Cadwaladr University Health Board, shared a post on LinkedIn:
“Your VWF activity assay might be giving you the wrong answer.
And that wrong answer changes everything downstream.
VWF:RCo has been the workhorse of VWD testing for decades.
But here’s what the data actually shows:
- VWF:RCo imprecision sits around 9%. GPIb-based assays? Around 3.2%.
- Ristocetin-sensitive polymorphisms can falsely lower the activity:Ag ratio. That’s not biology. That’s assay noise.
- In diverse populations, this creates a predictable disadvantage. The same patient, different ethnicity, different result. That’s an equity problem.
Why does this matter so much?
The VWF activity result sits at the centre of the subtype algorithm. I
f that number drifts, everything drifts with it:
- Type 1 patients get pushed into a Type 2 work-up
- Unnecessary multimers, RIPA, genetics referrals follow
- DDAVP decisions and perioperative plans change
- Borderline cases get missed entirely
VWF:GPIbM offers a way out.
No ristocetin dependence.
No polymorphism distortion.
92% Type 2 sensitivity. 85.1% Type 1 specificity. Same 0.70 activity:Ag ratio threshold. Same diagnostic logic.
The message is simple: modernise the assay, preserve the pathway.
Both BSH 2024 and ASH/ISTH 2021 guidelines point the same direction.
But this isn’t just a reagent swap.
It’s a quality programme.
- Validation
- Reporting language
- Clinical education
- Post-go-live review
All need to land together.
I built an interactive guide to walk laboratories through this transition step by step.
- Assay comparison
- Decision algorithms
- Implementation framework
- Rhe evidence behind each choice
All in one place.
Has your lab made this switch yet?
What held you back, or what pushed you forward?”
Other posts featuring Abdul Mannan on Hemostasis Today.
-
Apr 25, 2026, 03:502026 Applications Open for The International Outreach Initiative – ASH
-
Apr 25, 2026, 02:51Roche Extends Support to Expand Global Access to Hemophilia Care – WFH
-
Apr 25, 2026, 02:44WFH Congress 2026 Participation Overview – WFH
-
Apr 25, 2026, 02:33Sara Zalghout: Platelet Glycans as Diagnostic and Therapeutic Targets
-
Apr 25, 2026, 02:20Pierpaolo Di Micco: Proud to Be Published in JAMA for the Third Time in Four Years
-
Apr 25, 2026, 02:11Kathryn Golab: Coagulation QA Essentials for Reliable Lot to Lot Testing
-
Apr 24, 2026, 23:36Pedro Perez: Are We Measuring the Right Outcomes in VTE?
-
Apr 24, 2026, 20:41Christine Ngaruiya: Malvika Krishnamurthy Highlights Biomarker Gaps in Stroke Research at Stanford Research Symposium
-
Apr 24, 2026, 17:58Erwin Loh: Triple Combination Therapy Shows Major Benefit in Preventing Recurrent Stroke